CVS Health (NYSE:CVS) Rating Increased to Buy at Wall Street Zen

CVS Health (NYSE:CVS) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Thursday.

Several other research analysts also recently commented on CVS. Piper Sandler reiterated an “overweight” rating and set a $113.00 target price on shares of CVS Health in a research note on Monday, June 1st. DA Davidson increased their price target on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley lifted their price objective on shares of CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Bank of America increased their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Twenty-one investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and a consensus target price of $105.38.

CVS Health Stock Down 2.4%

CVS Health stock opened at $107.96 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The company’s 50-day moving average is $99.78 and its 200-day moving average is $85.78. The firm has a market capitalization of $137.75 billion, a PE ratio of 47.56, a P/E/G ratio of 1.08 and a beta of 0.61. CVS Health has a fifty-two week low of $58.50 and a fifty-two week high of $110.68.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. CVS Health’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts anticipate that CVS Health will post 7.46 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,441,551 shares of company stock worth $323,703,977. Insiders own 0.85% of the company’s stock.

Institutional Trading of CVS Health

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of CVS Health by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after purchasing an additional 1,824,424 shares during the period. State Street Corp lifted its position in CVS Health by 2.1% during the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares during the period. Capital International Investors grew its stake in CVS Health by 3.4% during the fourth quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after buying an additional 900,153 shares in the last quarter. Norges Bank bought a new stake in shares of CVS Health during the 4th quarter valued at approximately $1,666,265,000. Finally, Morgan Stanley increased its position in CVS Health by 6.3% during the 4th quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock worth $1,616,863,000 after purchasing an additional 1,211,631 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding its pharmacy offering to include select pet prescriptions nationwide, a move that could drive incremental foot traffic and sales. Pet medications now available at CVS Pharmacy®
• Positive Sentiment: Analysts and market commentary noted improving execution and a better payer margin outlook, which can reinforce confidence in CVS’s earnings trajectory. CVS Health Corporation (CVS) Rose on Improving Execution and Payer Margin Outlook
• Neutral Sentiment: CVS also highlighted ongoing community health investments in Massachusetts, underscoring its broader social and healthcare footprint, though the immediate stock impact appears limited. CVS Health Helping to Strengthen Communities Across Massachusetts
• Negative Sentiment: Henry Ford Health’s lawsuit alleging a 340B pricing scheme creates legal and reimbursement uncertainty, which could pressure sentiment around CVS’s pharmacy operations. Henry Ford Health sues CVS over alleged $29 million pricing scheme

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.